MARC Record from marc_columbia

LEADER: 08861cam a22009131i 4500
001 15199251
005 20220627134010.0
006 m d
007 cr |||||||||||
008 200724s2021 si a ob 000 0 eng d
035 $a(OCoLC)on1202850119
035 $a(NNC)15199251
040 $aUKMGB$beng$erda$epn$cUKMGB$dOCLCO$dUKAHL$dTYFRS$dOCLCF$dYDXIT$dTYFRS$dEBLCP$dYDX$dN$T$dOCLCO
066 $c(S
015 $aGBC094281$2bnb
016 7 $a019859445$2Uk
019 $a1198016149$a1202462119$a1202477610
020 $a9781003045410$q(electronic bk.)
020 $a1003045413$q(electronic bk.)
020 $a9781000067392$q(electronic bk. : Mobipocket)
020 $a1000067394$q(electronic bk. : Mobipocket)
020 $a9781000067385$q(electronic bk. : PDF)
020 $a1000067386$q(electronic bk. : PDF)
020 $a9781000067378$qelectronic publication
020 $a1000067378$qelectronic publication
020 $a9781000067354$qelectronic book
020 $a1000067351$qelectronic book
020 $a9781000067361$qMobipocket electronic book
020 $a100006736X$qMobipocket electronic book
020 $a9781003045397$qelectronic book
020 $a1003045391$qelectronic book
020 $z9789814877138$qhardcover
020 $z9814877131
024 7 $a10.1201/9781003045397$2doi
035 $a(OCoLC)1202850119$z(OCoLC)1198016149$z(OCoLC)1202462119$z(OCoLC)1202477610
037 $a9781000067378$bIngram Content Group
037 $a9781003045397$bTaylor & Francis
050 4 $aTP248.E5$bP53 2021
072 7 $aMED$x072000$2bisacsh
072 7 $aSCI$x010000$2bisacsh
072 7 $aSCI$x013000$2bisacsh
072 7 $aMQP$2bicssc
082 04 $a660.634$223
049 $aZCUA
245 00 $aPharmaceutical biocatalysis :$bimportant emzymes, novel targets, and therapies /$cedited by Peter Grunwald.
264 1 $aSingapore :$bJenny Stanford Publishing,$c[2021]
300 $a1 online resource :$billustrations (black and white, and colour).
336 $atext$2rdacontent
336 $astill image$2rdacontent
337 $acomputer$2rdamedia
338 $aonline resource$2rdacarrier
490 0 $aJenny Stanford series on biocatalysis ;$vvolume 6
504 $aIncludes bibliographical references.
520 $aThis volume of Pharmaceutical Biocatalysis starts with a discussion on the importance of biocatalytic synthesis approaches for a sustainable and environmentally friendly production of pharmaceuticals and active pharmaceutical ingredients. Among the enzymes discussed in detail with respect to their pharmaceutical relevance are cyclic nucleotide phosphodiesterases playing an important role in modulating signal transduction in various cell types; human DOPA decarboxylase, related to Parkinson's disease and aromatic amino acid decarboxylase deficiency; and phospholipase D enzymes as drug targets. Isocitrate dehydrogenase 1 and 2 mutations are novel therapeutic targets in acute myeloid leukemia. An additional chapter is devoted to the use of enzymes for prodrug activation in cancer therapy. The other topics include small-molecule inhibitors targeting receptor tyrosine kinases in cancer, -Lactams and related compounds as antibacterials, non-vitamin K oral anticoagulants for the treatment of thromboembolic diseases, and the molecular mechanisms for statin pleiotropy and its clinical relevance in cardiovascular diseases. The last chapter is a review of lysosomal storage disorders with an overview of approved drugs for treating these disorders by enzyme replacement therapy.
545 0 $aPeter Grunwald studied chemistry at the Universities of Saarbrücken and Hamburg, Germany. He graduated in the field of high-frequency spectroscopy and then became a staff member of the Institute of Physical Chemistry. After receiving his PhD in physical chemistry, he founded a biotechnology research group. He was appointed professor in 2001. His research interests focus on immobilized biocatalysts, kinetics of enzymes in organic solvents, and interactions between biocatalysts and heavy metal ions. Prof. Grunwald is also interested in chemical education, including curriculum development. He has authored a textbook on biochemistry and is an editorial board member of Catalysts.
588 $aDescription based on online resource; title from digital title page (viewed on January 05, 2021).
505 0 $aCover -- Half Title -- Series Page -- Title Page -- Copyright Page -- Contents -- Preface -- 1. Lipase-Mediated Biocatalysis as a Greener and Sustainable Choice for Pharmaceutical Processes -- 1.1 Introduction -- 1.2 Hydrolases as Biocatalysts -- 1.2.1 Lipases: A General Account -- 1.2.1.1 Structural features of lipases -- 1.2.1.2 Reaction mechanism of lipases -- 1.2.1.3 Properties of lipases -- 1.2.2 Lipase-Catalyzed Synthesis of Active Pharmaceutical Ingredients and Intermediates -- 1.2.2.1 Non-steroidal antiinflammatory drugs -- 1.2.2.2 Angiotensin-converting enzyme inhibitors
505 8 $a1.2.2.15 Cathepsin K inhibitor: Odanacatib intermediate -- 1.3 Commercial Success through Green Technologies -- 1.4 Future Perspectives -- 1.4.1 Protein Engineering -- 1.4.2 Directed Evolution -- 1.4.3 Artificial Intelligence -- 1.5 Conclusion -- 2. Phosphodiesterases -- 2.1 Introduction -- 2.2 Classification of PDE Subfamilies -- 2.3 Structural Aspects of Phosphodiesterases -- 2.4 Non-Specific Inhibition of Phosphodiesterases -- 2.5 Phosphodiesterase 3 -- 2.5.1 Structure, Function and Regulation of PDE3 -- 2.5.2 Inhibition of PDE3 -- 2.6 Phosphodiesterase 4
505 8 $a2.6.1 Structure, Function and Regulation of PDE4 -- 2.6.2 Inhibition of PDE4 -- 2.7 Phosphodiesterase 5 -- 2.7.1 Structure, Function and Regulation of PDE5 -- 2.7.2 Inhibition of PDE5 -- 2.8 Concluding Remarks -- 3. Human DOPA Decarboxylase: Catalysis and Involvement in Pharmacological Treatments for Parkinson's Disease and Aromatic Amino Acid Decarboxylase Deficiency -- 3.1 Introduction -- 3.2 Structure of DDC -- 3.3 Catalysis of DDC -- 3.4 Drugs Used to Counteract DDC Loss in PD or Loss-of-Function in AADC Deficiency -- 3.5 Conclusions
505 8 $a4. Advancing Phospholipase D Enzymes as Diverse Drug Targets -- 4.1 Introduction -- 4.2 Non-HKD PLD as a Target for Infectious Diseases and Envenoming -- 4.3 Non-HKD PLD as a Target for Cancer, Inflammatory and Neurodegenerative Diseases -- 4.4 Human PLD Inhibitors Are Potential Drugs for Cancer, Cardiovascular Disease, Infectious Diseases, and Neurodegenerative Diseases -- 4.5 Concluding Remarks -- 5. IDH1 and IDH2 Mutations as Novel Therapeutic Targets in Acute Myeloid Leukemia: Current Perspectives -- 5.1 Introduction -- 5.2 Normal Functions of IDH Enzymes
650 0 $aEnzymes$xIndustrial applications.
650 0 $aBiocatalysis.
650 0 $aPharmaceutical chemistry.
650 6 $aEnzymes$xApplications industrielles.
650 6 $aBiocatalyse.
650 6 $aChimie pharmaceutique.
650 7 $aMEDICAL / Pharmacy$2bisacsh
650 7 $aSCIENCE / Biotechnology$2bisacsh
650 7 $aSCIENCE / Chemistry / General$2bisacsh
650 7 $aBiocatalysis.$2fast$0(OCoLC)fst01896571
650 7 $aEnzymes$xIndustrial applications.$2fast$0(OCoLC)fst00913615
650 7 $aPharmaceutical chemistry.$2fast$0(OCoLC)fst01060115
655 0 $aElectronic books.
655 4 $aElectronic books.
700 1 $aGrunwald, Peter,$d1941-$eeditor.
776 08 $iPrint version:$z9789814877138
856 40 $uhttp://www.columbia.edu/cgi-bin/cul/resolve?clio15199251$zTaylor & Francis eBooks
880 $6500-00/(S$aLipase-Mediated Biocatalysis as a Greener and Sustainable Choice for Pharmaceutical Processes Monika Sharma, Tanya Bajaj, and Rohit Sharma -- Phosphodiesterases Moritz Helmstädter, Manfred Schubert-Zsilavecz -- Human DOPA Decarboxylase: Catalysis and Involvement in Pharmacological Treatments for Parkinson's Disease and Aromatic Amino Acid Decarboxylase Deficiency Mariarita Bertoldi and Giada Rossignoli -- Advancing Phospholipase D Enzymes as Diverse Drug Targets Hortensia Gomes Leal and Kimberly A. Stieglitz -- IDH1 and IDH2 Mutations as Novel Therapeutic Targets in Acute Myeloid Leukemia (AML): Current PerspectivesAngelo Paci et al. -- Enzymes for Prodrug-Activation in Cancer Treatment and Gene Therapies Peter Grunwald -- Small-Molecule Inhibitors Targeting Receptor Tyrosine Kinases in Cancer Mohammad Hojjat-Farsangi and Reza Khamisipour -- β-Lactams and Related Compounds as Antibacterials and β-Lactamase Inhibitors Ulrike Holzgrabe and Jens Schmitz -- Non-Vitamin K Oral Anticoagulants (NOACs): New Options Susanne Alban -- Molecular Mechanisms for Statin Pleiotropy and Possible Clinical Relevance in Cardiovascular Disease J. K. Liao -- Lysosomal Storage Disorders and Enzyme Replacement Therapy Peter Grunwald
852 8 $blweb$hEBOOKS